Literature DB >> 19130174

25 years of the antiphospholipid syndrome: lights and shadows on the primary prophylaxis of asymptomatic patients with confirmed positivity of antiphospholipid antibodies.

Laura Andreoli, Angela Tincani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19130174     DOI： 10.1007/s11739-008-0222-3

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  16 in total

1.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).

Authors:  S Miyakis; M D Lockshin; T Atsumi; D W Branch; R L Brey; R Cervera; R H W M Derksen; P G DE Groot; T Koike; P L Meroni; G Reber; Y Shoenfeld; A Tincani; P G Vlachoyiannopoulos; S A Krilis
Journal:  J Thromb Haemost       Date:  2006-02       Impact factor: 5.824

2.  Invitation to a debate on the serological criteria that define the antiphospholipid syndrome.

Authors:  M Galli; G Reber; P de Moerloose; P G de Groot
Journal:  J Thromb Haemost       Date:  2007-12-07       Impact factor: 5.824

Review 3.  Antiphospholipid syndrome dilemmas still to be solved: 2008 status.

Authors:  Yehuda Shoenfeld; Pier Luigi Meroni; Ricard Cervera
Journal:  Ann Rheum Dis       Date:  2008-04       Impact factor: 19.103

4.  Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study.

Authors:  A Ruffatti; T Del Ross; M Ciprian; M Nuzzo; M Rampudda; M T Bertero; R Bergia; P Caramaschi; D Biasi; F Capsoni; L Montaguti; R Ruffini; A Brucato; U Picillo; V Fanelli; V Riccieri; A Piccoli; G Valesini; A Doria; P L Meroni; A Tincani
Journal:  Ann Rheum Dis       Date:  2008-09-23       Impact factor: 19.103

5.  Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? Yes (in some cases).

Authors:  Maria Gerosa; Cecilia Chighizola; Pier Luigi Meroni
Journal:  Intern Emerg Med       Date:  2008-07-01       Impact factor: 3.397

6.  Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men.

Authors:  O Vaarala; M Mänttäri; V Manninen; L Tenkanen; M Puurunen; K Aho; T Palosuo
Journal:  Circulation       Date:  1995-01-01       Impact factor: 29.690

7.  Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry.

Authors:  G Finazzi; V Brancaccio; M Moia; N Ciaverella; M G Mazzucconi; P C Schinco; M Ruggeri; E M Pogliani; G Gamba; E Rossi; F Baudo; C Manotti; A D'Angelo; G Palareti; V De Stefano; M Berrettini; T Barbui
Journal:  Am J Med       Date:  1996-05       Impact factor: 4.965

8.  Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  William H Geerts; David Bergqvist; Graham F Pineo; John A Heit; Charles M Samama; Michael R Lassen; Clifford W Colwell
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

9.  Management of the controversial aspects of the antiphospholipid syndrome pregnancies: a guide for clinicians and researchers.

Authors:  D Erkan; S Patel; M Nuzzo; M Gerosa; P L Meroni; A Tincani; M D Lockshin
Journal:  Rheumatology (Oxford)       Date:  2008-06       Impact factor: 7.580

Review 10.  Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms.

Authors:  Silvia S Pierangeli; Pojen P Chen; Elena Raschi; Silvia Scurati; Claudia Grossi; Maria Orietta Borghi; Ivan Palomo; E Nigel Harris; Pier Luigi Meroni
Journal:  Semin Thromb Hemost       Date:  2008-04       Impact factor: 4.180
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.